(S1 (S (S (NP (NN Oroxylin) (NN A)) (VP (VBZ prevents) (NP (JJ inflammation-related) (NN tumor)) (PP (IN through) (NP (NP (NN down-regulation)) (PP (IN of) (NP (JJ inflammatory) (NN gene) (NN expression))))) (PP (IN by) (S (VP (VBG inhibiting) (NP (NN NF-kappaB) (NN signaling))))))) (. .)))
(S1 (S (S (NP (VBG Increasing) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ inflammatory) (NN microenvironment)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN at) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (NN tumor) (NN development)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NP (NN inflammation)) (CC and) (NP (NN proliferation))) (PP (IN of) (NP (NN cancer) (NNS cells)))))))) (VP (VBP remain) (ADVP (RB poorly)) (VP (VBN defined)))) (. .)))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VP (VBD reported) (NP (NP (DT the) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NN oroxylin) (NN A))) (PP (IN on) (NP (NP (DT the) (JJ inflammation-stimulated) (NN proliferation)) (PP (IN of) (NP (NN tumor) (NNS cells))))))) (CC and) (VP (VBD delineated) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (PRP$ its) (NN action))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NN oroxylin) (NN A)))) (VP (VBD inhibited) (NP (NP (NN NF-kappaB) (NN p65) (JJ nuclear) (NN translocation)) (CC and) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (NN IkappaBalpha)) (CC and) (NP (NN IKKalpha/beta)))))) (PP (IN in) (NP (CC both) (NP (JJ human) (NN colon) (NN tumor) (NN HCT116) (NNS cells)) (CC and) (NP (JJ human) (NNS monocytes)) (NP (NN THP-1) (NNS cells))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (PP (IN in) (NP (NN THP-1) (NNS cells))) (, ,) (S (NP (NN oroxylin) (NN A)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NP (ADJP (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-))) (JJ -induced)) (NN secretion)) (PP (IN of) (NP (NP (JJ prototypical) (JJ proinflammatory) (NN cytokine) (NN IL-6)) (CONJP (CC but) (RB not)) (NP (NN IL-1beta))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBD was) (VP (VBN confirmed) (PP (IN at) (NP (DT the) (NN transcription) (NN level))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NN oroxylin) (NN A)) (VP (VBD inhibited) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (NP (NN HCT116) (NNS cells)) (VP (VBN stimulated) (PP (IN by) (NP (NP (JJ LPS-induced) (NN THP-1) (NNS cells)) (PP (IN in) (NP (NN co-culture) (NN microenvironment))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN oroxylin) (NN A)) (VP (VP (VBD modulated) (NP (NP (NN NF-kappaB) (NN signaling) (NN pathway)) (VP (VBN involved) (PP (IN in) (NP (NP (JJ inflammation-induced) (NN cancer) (NN initiation)) (CC and) (NP (NN progression))))))) (CC and) (VP (ADVP (RB therefore)) (VP (MD could) (VP (VB be) (NP (NP (DT a) (JJ potential) (NN cancer) (NN chemoprevention) (NN agent)) (PP (IN for) (NP (JJ inflammation-related) (NN cancer))))))))) (. .)))
(S1 (S (S (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-)) (NP (NN 2012)) (NP (NNP Wiley) (NNP Periodicals) (, ,) (NNP Inc))) (. .)))
